Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeuti...
Ausführliche Beschreibung
Autor*in: |
Antoni Torres [verfasserIn] Anna Motos [verfasserIn] Denise Battaglini [verfasserIn] Gianluigi Li Bassi [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2018 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Critical Care - BMC, 2015, 22(2018), 1, Seite 6 |
---|---|
Übergeordnetes Werk: |
volume:22 ; year:2018 ; number:1 ; pages:6 |
Links: |
---|
DOI / URN: |
10.1186/s13054-018-1958-4 |
---|
Katalog-ID: |
DOAJ073469041 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ073469041 | ||
003 | DE-627 | ||
005 | 20230309115127.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230228s2018 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s13054-018-1958-4 |2 doi | |
035 | |a (DE-627)DOAJ073469041 | ||
035 | |a (DE-599)DOAJf67bf3dbc05f48c084cbe29fdc19aaee | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC86-88.9 | |
100 | 0 | |a Antoni Torres |e verfasserin |4 aut | |
245 | 1 | 0 | |a Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects |
264 | 1 | |c 2018 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials. | ||
650 | 4 | |a Pseudomonas aeruginosa | |
650 | 4 | |a Amikacin | |
650 | 4 | |a Ventilator-associated pneumonia | |
650 | 4 | |a Gram-negative bacteria | |
653 | 0 | |a Medical emergencies. Critical care. Intensive care. First aid | |
700 | 0 | |a Anna Motos |e verfasserin |4 aut | |
700 | 0 | |a Denise Battaglini |e verfasserin |4 aut | |
700 | 0 | |a Gianluigi Li Bassi |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Critical Care |d BMC, 2015 |g 22(2018), 1, Seite 6 |w (DE-627)331258269 |w (DE-600)2051256-9 |x 1466609X |7 nnns |
773 | 1 | 8 | |g volume:22 |g year:2018 |g number:1 |g pages:6 |
856 | 4 | 0 | |u https://doi.org/10.1186/s13054-018-1958-4 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/f67bf3dbc05f48c084cbe29fdc19aaee |z kostenfrei |
856 | 4 | 0 | |u http://link.springer.com/article/10.1186/s13054-018-1958-4 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1364-8535 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 22 |j 2018 |e 1 |h 6 |
author_variant |
a t at a m am d b db g l b glb |
---|---|
matchkey_str |
article:1466609X:2018----::naeaiaifreeermeaieumnrifcinitenesvcruicr |
hierarchy_sort_str |
2018 |
callnumber-subject-code |
RC |
publishDate |
2018 |
allfields |
10.1186/s13054-018-1958-4 doi (DE-627)DOAJ073469041 (DE-599)DOAJf67bf3dbc05f48c084cbe29fdc19aaee DE-627 ger DE-627 rakwb eng RC86-88.9 Antoni Torres verfasserin aut Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials. Pseudomonas aeruginosa Amikacin Ventilator-associated pneumonia Gram-negative bacteria Medical emergencies. Critical care. Intensive care. First aid Anna Motos verfasserin aut Denise Battaglini verfasserin aut Gianluigi Li Bassi verfasserin aut In Critical Care BMC, 2015 22(2018), 1, Seite 6 (DE-627)331258269 (DE-600)2051256-9 1466609X nnns volume:22 year:2018 number:1 pages:6 https://doi.org/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/article/f67bf3dbc05f48c084cbe29fdc19aaee kostenfrei http://link.springer.com/article/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/toc/1364-8535 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2018 1 6 |
spelling |
10.1186/s13054-018-1958-4 doi (DE-627)DOAJ073469041 (DE-599)DOAJf67bf3dbc05f48c084cbe29fdc19aaee DE-627 ger DE-627 rakwb eng RC86-88.9 Antoni Torres verfasserin aut Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials. Pseudomonas aeruginosa Amikacin Ventilator-associated pneumonia Gram-negative bacteria Medical emergencies. Critical care. Intensive care. First aid Anna Motos verfasserin aut Denise Battaglini verfasserin aut Gianluigi Li Bassi verfasserin aut In Critical Care BMC, 2015 22(2018), 1, Seite 6 (DE-627)331258269 (DE-600)2051256-9 1466609X nnns volume:22 year:2018 number:1 pages:6 https://doi.org/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/article/f67bf3dbc05f48c084cbe29fdc19aaee kostenfrei http://link.springer.com/article/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/toc/1364-8535 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2018 1 6 |
allfields_unstemmed |
10.1186/s13054-018-1958-4 doi (DE-627)DOAJ073469041 (DE-599)DOAJf67bf3dbc05f48c084cbe29fdc19aaee DE-627 ger DE-627 rakwb eng RC86-88.9 Antoni Torres verfasserin aut Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials. Pseudomonas aeruginosa Amikacin Ventilator-associated pneumonia Gram-negative bacteria Medical emergencies. Critical care. Intensive care. First aid Anna Motos verfasserin aut Denise Battaglini verfasserin aut Gianluigi Li Bassi verfasserin aut In Critical Care BMC, 2015 22(2018), 1, Seite 6 (DE-627)331258269 (DE-600)2051256-9 1466609X nnns volume:22 year:2018 number:1 pages:6 https://doi.org/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/article/f67bf3dbc05f48c084cbe29fdc19aaee kostenfrei http://link.springer.com/article/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/toc/1364-8535 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2018 1 6 |
allfieldsGer |
10.1186/s13054-018-1958-4 doi (DE-627)DOAJ073469041 (DE-599)DOAJf67bf3dbc05f48c084cbe29fdc19aaee DE-627 ger DE-627 rakwb eng RC86-88.9 Antoni Torres verfasserin aut Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials. Pseudomonas aeruginosa Amikacin Ventilator-associated pneumonia Gram-negative bacteria Medical emergencies. Critical care. Intensive care. First aid Anna Motos verfasserin aut Denise Battaglini verfasserin aut Gianluigi Li Bassi verfasserin aut In Critical Care BMC, 2015 22(2018), 1, Seite 6 (DE-627)331258269 (DE-600)2051256-9 1466609X nnns volume:22 year:2018 number:1 pages:6 https://doi.org/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/article/f67bf3dbc05f48c084cbe29fdc19aaee kostenfrei http://link.springer.com/article/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/toc/1364-8535 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2018 1 6 |
allfieldsSound |
10.1186/s13054-018-1958-4 doi (DE-627)DOAJ073469041 (DE-599)DOAJf67bf3dbc05f48c084cbe29fdc19aaee DE-627 ger DE-627 rakwb eng RC86-88.9 Antoni Torres verfasserin aut Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials. Pseudomonas aeruginosa Amikacin Ventilator-associated pneumonia Gram-negative bacteria Medical emergencies. Critical care. Intensive care. First aid Anna Motos verfasserin aut Denise Battaglini verfasserin aut Gianluigi Li Bassi verfasserin aut In Critical Care BMC, 2015 22(2018), 1, Seite 6 (DE-627)331258269 (DE-600)2051256-9 1466609X nnns volume:22 year:2018 number:1 pages:6 https://doi.org/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/article/f67bf3dbc05f48c084cbe29fdc19aaee kostenfrei http://link.springer.com/article/10.1186/s13054-018-1958-4 kostenfrei https://doaj.org/toc/1364-8535 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2018 1 6 |
language |
English |
source |
In Critical Care 22(2018), 1, Seite 6 volume:22 year:2018 number:1 pages:6 |
sourceStr |
In Critical Care 22(2018), 1, Seite 6 volume:22 year:2018 number:1 pages:6 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Pseudomonas aeruginosa Amikacin Ventilator-associated pneumonia Gram-negative bacteria Medical emergencies. Critical care. Intensive care. First aid |
isfreeaccess_bool |
true |
container_title |
Critical Care |
authorswithroles_txt_mv |
Antoni Torres @@aut@@ Anna Motos @@aut@@ Denise Battaglini @@aut@@ Gianluigi Li Bassi @@aut@@ |
publishDateDaySort_date |
2018-01-01T00:00:00Z |
hierarchy_top_id |
331258269 |
id |
DOAJ073469041 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ073469041</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309115127.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s13054-018-1958-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ073469041</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf67bf3dbc05f48c084cbe29fdc19aaee</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC86-88.9</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Antoni Torres</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pseudomonas aeruginosa</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Amikacin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ventilator-associated pneumonia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gram-negative bacteria</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical emergencies. Critical care. Intensive care. First aid</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Motos</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Denise Battaglini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gianluigi Li Bassi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Critical Care</subfield><subfield code="d">BMC, 2015</subfield><subfield code="g">22(2018), 1, Seite 6</subfield><subfield code="w">(DE-627)331258269</subfield><subfield code="w">(DE-600)2051256-9</subfield><subfield code="x">1466609X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s13054-018-1958-4</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f67bf3dbc05f48c084cbe29fdc19aaee</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://link.springer.com/article/10.1186/s13054-018-1958-4</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1364-8535</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2018</subfield><subfield code="e">1</subfield><subfield code="h">6</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Antoni Torres |
spellingShingle |
Antoni Torres misc RC86-88.9 misc Pseudomonas aeruginosa misc Amikacin misc Ventilator-associated pneumonia misc Gram-negative bacteria misc Medical emergencies. Critical care. Intensive care. First aid Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects |
authorStr |
Antoni Torres |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)331258269 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC86-88 |
illustrated |
Not Illustrated |
issn |
1466609X |
topic_title |
RC86-88.9 Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects Pseudomonas aeruginosa Amikacin Ventilator-associated pneumonia Gram-negative bacteria |
topic |
misc RC86-88.9 misc Pseudomonas aeruginosa misc Amikacin misc Ventilator-associated pneumonia misc Gram-negative bacteria misc Medical emergencies. Critical care. Intensive care. First aid |
topic_unstemmed |
misc RC86-88.9 misc Pseudomonas aeruginosa misc Amikacin misc Ventilator-associated pneumonia misc Gram-negative bacteria misc Medical emergencies. Critical care. Intensive care. First aid |
topic_browse |
misc RC86-88.9 misc Pseudomonas aeruginosa misc Amikacin misc Ventilator-associated pneumonia misc Gram-negative bacteria misc Medical emergencies. Critical care. Intensive care. First aid |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Critical Care |
hierarchy_parent_id |
331258269 |
hierarchy_top_title |
Critical Care |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)331258269 (DE-600)2051256-9 |
title |
Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects |
ctrlnum |
(DE-627)DOAJ073469041 (DE-599)DOAJf67bf3dbc05f48c084cbe29fdc19aaee |
title_full |
Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects |
author_sort |
Antoni Torres |
journal |
Critical Care |
journalStr |
Critical Care |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2018 |
contenttype_str_mv |
txt |
container_start_page |
6 |
author_browse |
Antoni Torres Anna Motos Denise Battaglini Gianluigi Li Bassi |
container_volume |
22 |
class |
RC86-88.9 |
format_se |
Elektronische Aufsätze |
author-letter |
Antoni Torres |
doi_str_mv |
10.1186/s13054-018-1958-4 |
author2-role |
verfasserin |
title_sort |
inhaled amikacin for severe gram-negative pulmonary infections in the intensive care unit: current status and future prospects |
callnumber |
RC86-88.9 |
title_auth |
Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects |
abstract |
Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials. |
abstractGer |
Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials. |
abstract_unstemmed |
Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
1 |
title_short |
Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects |
url |
https://doi.org/10.1186/s13054-018-1958-4 https://doaj.org/article/f67bf3dbc05f48c084cbe29fdc19aaee http://link.springer.com/article/10.1186/s13054-018-1958-4 https://doaj.org/toc/1364-8535 |
remote_bool |
true |
author2 |
Anna Motos Denise Battaglini Gianluigi Li Bassi |
author2Str |
Anna Motos Denise Battaglini Gianluigi Li Bassi |
ppnlink |
331258269 |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1186/s13054-018-1958-4 |
callnumber-a |
RC86-88.9 |
up_date |
2024-07-03T17:51:12.270Z |
_version_ |
1803581204487733248 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ073469041</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309115127.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s13054-018-1958-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ073469041</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf67bf3dbc05f48c084cbe29fdc19aaee</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC86-88.9</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Antoni Torres</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pseudomonas aeruginosa</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Amikacin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ventilator-associated pneumonia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gram-negative bacteria</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical emergencies. Critical care. Intensive care. First aid</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Motos</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Denise Battaglini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gianluigi Li Bassi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Critical Care</subfield><subfield code="d">BMC, 2015</subfield><subfield code="g">22(2018), 1, Seite 6</subfield><subfield code="w">(DE-627)331258269</subfield><subfield code="w">(DE-600)2051256-9</subfield><subfield code="x">1466609X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s13054-018-1958-4</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f67bf3dbc05f48c084cbe29fdc19aaee</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://link.springer.com/article/10.1186/s13054-018-1958-4</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1364-8535</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2018</subfield><subfield code="e">1</subfield><subfield code="h">6</subfield></datafield></record></collection>
|
score |
7.399748 |